EP3609329A4 - Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors - Google Patents

Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors Download PDF

Info

Publication number: EP3609329A4
Authority: EP; European Patent Office
Prior art keywords: posaconazole; sensitization; compositions; methods; resistant tumors
Prior art date: 2017-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP18783809.9A

Other languages

German (de)

French (fr)

Other versions

EP3609329A1 (en

Inventor

Vikash J. BHAGWANDIN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-12

Filing date

2018-04-12

Publication date

2021-03-17

2018-04-12 Application filed by Individual filed Critical Individual

2020-02-19 Publication of EP3609329A1 publication Critical patent/EP3609329A1/en

2021-03-17 Publication of EP3609329A4 publication Critical patent/EP3609329A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP18783809.9A 2017-04-12 2018-04-12 Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors Withdrawn EP3609329A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762484852P	2017-04-12	2017-04-12
PCT/US2018/027371 WO2018191541A1 (en)	2017-04-12	2018-04-12	Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors

Publications (2)

Publication Number	Publication Date
EP3609329A1 EP3609329A1 (en)	2020-02-19
EP3609329A4 true EP3609329A4 (en)	2021-03-17

Family

ID=63793667

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18783809.9A Withdrawn EP3609329A4 (en)	2017-04-12	2018-04-12	Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors

Country Status (6)

Country	Link
EP (1)	EP3609329A4 (en)
KR (1)	KR20200059188A (en)
CN (1)	CN111093373A (en)
AU (1)	AU2018253189A1 (en)
CA (1)	CA3063115A1 (en)
WO (1)	WO2018191541A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013037043A1 (en) *	2011-09-13	2013-03-21	Universite De Montreal	Combination therapy using ribavirin as eif4e inhibitor
US20140315920A1 (en) *	2013-04-17	2014-10-23	Hedgepath, Llc.	Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2016011328A1 (en) *	2014-07-17	2016-01-21	Baker Cheryl	Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005249502A1 (en) *	2004-05-28	2005-12-15	Schering Corporation	Particulate-stabilized injectable pharmaceutical compositions of posaconazole
WO2006039569A1 (en) *	2004-09-30	2006-04-13	The University Of Chicago	Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
AU2006258461B2 (en) *	2005-06-14	2011-08-25	Aska Pharmaceutical Co., Ltd.	Thienopyrimidine derivative
US8653083B2 (en) *	2005-08-22	2014-02-18	The Johns Hopkins University	Hedgehog pathway antagonists to treat disease
JP5205034B2 (en) *	2007-11-06	2013-06-05	ローム株式会社	Surface emitting laser diode
WO2012006584A2 (en) *	2010-07-08	2012-01-12	Infinity Pharmaceuticals, Inc.	Therapeutic regimens for hedgehog-associated cancers

2018
- 2018-04-12 WO PCT/US2018/027371 patent/WO2018191541A1/en not_active Ceased
- 2018-04-12 KR KR1020197033474A patent/KR20200059188A/en not_active Ceased
- 2018-04-12 AU AU2018253189A patent/AU2018253189A1/en not_active Abandoned
- 2018-04-12 CA CA3063115A patent/CA3063115A1/en not_active Abandoned
- 2018-04-12 CN CN201880038812.1A patent/CN111093373A/en active Pending
- 2018-04-12 EP EP18783809.9A patent/EP3609329A4/en not_active Withdrawn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013037043A1 (en) *	2011-09-13	2013-03-21	Universite De Montreal	Combination therapy using ribavirin as eif4e inhibitor
US20140315920A1 (en) *	2013-04-17	2014-10-23	Hedgepath, Llc.	Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2016011328A1 (en) *	2014-07-17	2016-01-21	Baker Cheryl	Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018191541A1 *

Also Published As

Publication number	Publication date
EP3609329A1 (en)	2020-02-19
KR20200059188A (en)	2020-05-28
CN111093373A (en)	2020-05-01
AU2018253189A1 (en)	2019-12-05
WO2018191541A1 (en)	2018-10-18
CA3063115A1 (en)	2018-10-18

Similar Documents

Publication	Publication Date	Title
SG11202104687SA (en)	2021-06-29	Ret inhibitors, pharmaceutical compositions and uses thereof
IL261963A (en)	2018-11-29	Antibodies, pharmaceutical compositions and methods
EP3891148A4 (en)	2022-09-07	Ret inhibitors, pharmaceutical compositions and uses thereof
EP3665156A4 (en)	2021-04-28	Compounds, compositions and methods
EP3585433A4 (en)	2020-12-30	Therapeutic compositions and related methods for photoimmunotherapy
IL254124A0 (en)	2017-10-31	Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
EP3491026A4 (en)	2020-07-29	Human antibodies, pharmaceutical compositions and methods
EP3675859A4 (en)	2021-06-30	Compounds, compositions, and methods for the treatment of disease
EP3597735A4 (en)	2020-11-25	Ctla4 antibody, pharmaceutical composition and use thereof
EP3129048A4 (en)	2017-10-25	Antibodies, pharmaceutical compositions and uses thereof
SG11202105730TA (en)	2021-06-29	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
EP3640248B8 (en)	2023-11-15	Aminopyrimidine derivatives, preparation method therefor and use thereof
PT3580208T (en)	2021-11-18	Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EP3381925A4 (en)	2018-10-03	Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
EP3124486A4 (en)	2017-08-23	Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
EP3664797A4 (en)	2021-02-17	Nr4a1 ligands, pharmaceutical compositions, and related methods of use
HK1254231A1 (en)	2019-07-12	Mito-honokiol compounds and methods of synthesis and use thereof
EP3284743A4 (en)	2018-04-25	Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
EP3630090A4 (en)	2021-04-07	Combination therapy for cancer using botanical compositions and enzalutamide
EP3303320A4 (en)	2018-12-05	Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
EP3645008A4 (en)	2020-12-09	Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation.
EP3596082A4 (en)	2020-12-16	Cdpk1 inhibitors, compositions and methods related thereto
EP3665165A4 (en)	2021-08-11	Dhfr inhibitors, compositions, and methods related thereto
HK40013994A (en)	2020-08-14	Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
EP3609329A4 (en)	2021-03-17	Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors

Legal Events

Date	Code	Title	Description
2018-10-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-01-17	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-01-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-02-19	17P	Request for examination filed	Effective date: 20191112
2020-02-19	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-02-19	AX	Request for extension of the european patent	Extension state: BA ME
2020-07-22	DAV	Request for validation of the european patent (deleted)
2020-07-22	DAX	Request for extension of the european patent (deleted)
2020-08-14	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40013994 Country of ref document: HK
2021-03-17	A4	Supplementary search report drawn up and despatched	Effective date: 20210211
2021-03-17	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 45/06 20060101ALI20210205BHEP Ipc: A61K 31/475 20060101ALI20210205BHEP Ipc: A61P 35/00 20060101ALI20210205BHEP Ipc: A01N 43/48 20060101AFI20210205BHEP Ipc: A61K 31/496 20060101ALI20210205BHEP Ipc: A61K 31/337 20060101ALI20210205BHEP
2024-02-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2024-03-20	18D	Application deemed to be withdrawn	Effective date: 20231101